BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34160334)

  • 1. Trends in the use of hormonal contraception in Estonia 2005-2019 and the risk of arterial and venous thromboembolism: a population-based study.
    Kurvits K; Laius O; Uusküla M; Laanpere M
    Eur J Contracept Reprod Health Care; 2021 Oct; 26(5):413-420. PubMed ID: 34160334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.
    Tepper NK; Dragoman MV; Gaffield ME; Curtis KM
    Contraception; 2017 Feb; 95(2):130-139. PubMed ID: 27771476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.
    Ramanadhan S; Hansen K; Henderson JT; Cohen MA; Paynter R; Edelman A
    Cochrane Database Syst Rev; 2023 May; 5(5):CD014908. PubMed ID: 37184292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
    Plu-Bureau G; Sabbagh E; Hugon-Rodin J
    Gynecol Obstet Fertil Senol; 2018 Dec; 46(12):823-833. PubMed ID: 30389542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal contraception and risk of venous thromboembolism: national follow-up study.
    Lidegaard Ø; Løkkegaard E; Svendsen AL; Agger C
    BMJ; 2009 Aug; 339():b2890. PubMed ID: 19679613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.
    Dragoman M; Curtis KM; Gaffield ME
    Contraception; 2016 Sep; 94(3):280-7. PubMed ID: 26272309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic diseases in young women and the influence of oral contraceptives.
    Lidegaard O
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S62-7. PubMed ID: 9753312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.
    Iversen L; Fielding S; Lidegaard Ø; Mørch LS; Skovlund CW; Hannaford PC
    BMJ; 2018 Sep; 362():k3609. PubMed ID: 30257920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Peroral hormonal contraception and risk of venous thromboembolism].
    Ludka O; Spinar J; Musil V; Pozdísek Z
    Vnitr Lek; 2010 May; 56(5):370-5. PubMed ID: 20578585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
    Hugon-Rodin J; Horellou MH; Conard J; Gompel A; Plu-Bureau G
    Thromb Haemost; 2018 May; 118(5):922-928. PubMed ID: 29614525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis.
    Glisic M; Shahzad S; Tsoli S; Chadni M; Asllanaj E; Rojas LZ; Brown E; Chowdhury R; Muka T; Franco OH
    Eur J Prev Cardiol; 2018 Jul; 25(10):1042-1052. PubMed ID: 29745237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?
    Han L; Jensen JT
    Obstet Gynecol Clin North Am; 2015 Dec; 42(4):683-98. PubMed ID: 26598309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception.
    Bala NS; Stanek JR; Vesely SK; Cronin RM; Creary SE; Roe AH; Xu W; O'Brien SH
    Blood Adv; 2023 Oct; 7(20):6140-6150. PubMed ID: 37585480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism in women taking hormonal contraceptives.
    Blanco-Molina A; Monreal M
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):211-5. PubMed ID: 20136607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic hormonal contraception and risk of venous thromboembolism.
    Heikinheimo O; Toffol E; Partonen T; But A; Latvala A; Haukka J
    Acta Obstet Gynecol Scand; 2022 Aug; 101(8):846-855. PubMed ID: 35633036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal contraception and thrombosis.
    Sitruk-Ware R
    Fertil Steril; 2016 Nov; 106(6):1289-1294. PubMed ID: 27678035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women.
    Sugiura K; Kobayashi T; Ojima T
    Thromb Res; 2016 Jan; 137():11-16. PubMed ID: 26672897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile and recurrence rate in women with venous thromboembolism during combined hormonal contraceptive use: a prospective cohort study.
    van Vlijmen EF; Mäkelburg AB; Knol HM; Tichelaar VI; Kluin-Nelemans HC; Veeger NJ; Meijer K
    Br J Haematol; 2016 Feb; 172(4):636-8. PubMed ID: 26105591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.